<DOC>
	<DOCNO>NCT02488421</DOCNO>
	<brief_summary>The purpose study determine compare persistence rate newly prescribe apixaban , rivaroxaban , dabigatran VKAs patient NVAF .</brief_summary>
	<brief_title>Real Evidence Anticoagulation Treatment Non-valvular Atrial Fibrillation Germany , UK France : REACT-AF2</brief_title>
	<detailed_description>Actual number patient enrol UK : 15242 patient Actual number patient enrol Germany : 22880 patient</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Have apixaban , rivaroxaban , dabigatran VKA prescription study period Are ≥18 year old index date Have ≥12 month computerise medical data prior index date Have record AF ever prior index date ( index OAC prescription ) Have record valvular condition ( ie , rheumatic valvular disease prosthetic valve ) ever prior index date Have history ( ever prior index date ) Oral anticoagulant ( OACs ) prescribe study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>